FindDrugs.org

Mochi Health Review

Brand-level review · Last reviewed Sep 14, 2026

5.54/10

Operator-trust score

The brand-level factors every category shares — legitimacy, clinical oversight, transparency, privacy, policy, support — not price or per-treatment value.

How much separate evidence is behind this score

This score is made of 8 factors resting on 6 distinct pieces of evidence, because some factors were assessed from the same recorded signal:

  • Support & Care Model (64) · Access & Speed (64) · Transparency & Disclosure (62)“Mochi publishes membership and medication pricing on its own site: $39 first month then $79/month membership, with compounded semaglutide from $59 and tirzepatide from $71. Published pre-signup, which is better disclosur…”

We publish this because a factor scored from evidence another factor also rests on is not independent of it. The score stands as computed; the methodology explains what that means for reading one.

Lowest costClinician accessCash-payInsurance-billed

Our verdict

Mochi Health is a San Francisco telehealth company whose weight-management programme requires a live video visit with a board-certified obesity-medicine provider — a stronger model than the asynchronous questionnaire most of this category runs on — and which publishes its membership and medication pricing before signup. Its operator-trust score is 5.54 — the brand-level factors every category shares, not price or per-treatment value. It is held down by a regulator’s action against its own affiliated compounding pharmacy, by two pending manufacturer lawsuits, and by a concentration of cancellation and continued-billing complaints.

Mochi Health plans & reviews by category

Each category is scored separately. Read the full review where one exists — or check current pricing directly.

Weight Loss / GLP-1

6.00/10
Read the Weight Loss / GLP-1 reviewCheck price
  • Semaglutide · injection$178/mo
  • Tirzepatide · injection$278/mo
  • Other · injectionBranded GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro) via insurance; membership includes prior-authorization assistance

Prices as of Sep 14, 2026 — verify current on the brand's site.

Key takeaways

  • Requires a real-time video visit with a licensed provider before prescribing — a genuine differentiator in this category.
  • Publishes membership and medication pricing on its own site before signup, which is better disclosure than most of this set.
  • Its compounder Aequita Pharmacy drew an immediate Limited Stop Service from Washington State's Pharmacy Quality Assurance Commission, on findings of untrained and unqualified staff performing sterile compounding and failure to adhere to sterile compounding procedures.
  • Two manufacturers have sued it over compounded GLP-1s — Eli Lilly (No. 3:25-cv-03534) and Novo Nordisk (No. 5:25-cv-06563), both N.D. Cal. Both are untested allegations in pending complaints, neither adjudicated.
  • Prescription sales are final and nonrefundable, the cancellation window is narrow and not clearly disclosed, and complaints cluster on continued billing after cancellation — BBB B- with roughly 1,296 complaints.
  • Its accreditation and privacy claims appear on neither its own page nor a retrievable certification record, and its privacy practices are not detailed publicly; no breach is on the HHS OCR register for it.

What is Mochi Health?

Mochi Health is a telehealth company founded in 2022 and headquartered in San Francisco, spanning 120+ conditions with weight management as its flagship. For weight management it connects patients with board-certified obesity-medicine providers and registered dietitians, and prescribes compounded semaglutide and tirzepatide or branded GLP-1s through insurance. It states on its own About page that it operates with board-certified providers in all 50 states, and lists 400+ named providers with their credentials — one of the few operators in this set that names anyone at all.

Is Mochi Health legit?

Mixed. Mochi Health is a real telehealth operator working across all 50 states with board-certified obesity-medicine providers, and it requires a live video visit before prescribing rather than a questionnaire. The central caveat is its own affiliated compounding pharmacy, Aequita, which drew a Washington State Limited Stop Service over untrained staff and sterile-compounding deficiencies and was subsequently closed. Its accreditation and HIPAA claims are asserted by third parties and could not be independently verified, because the public registry is not retrievable by us.

  • Licensed & accredited: Operates in all 50 states with board-certified obesity-medicine providers — joinmochi.com/about, Aug 2026. Its LegitScript and HIPAA claims could not be independently verified.
  • Clinician model: Requires a live video visit with board-certified obesity-medicine providers — a stronger-than-async model on paper — NBC Bay Area, Jul 2026.
  • Medication & pharmacy: Its affiliated Aequita compounder drew a Washington DOH Pharmacy Quality Assurance Commission immediate Limited Stop Service for untrained/unqualified staff and sterile-compounding deficiencies that placed patient safety at risk, and that pharmacy was subsequently closed — Washington State DOH enforcement record (doh.wa.gov).
  • Watch-outs: The pharmacy-safety issues were not proactively disclosed to consumers, and we could not find published BMI/age eligibility thresholds (/eligibility returned 404) — Mochi (joinmochi.com), Jul 2026.

Treatment options

What Mochi Health actually treats. Pricing lives in the plans table above and in each category review.

  • Weight loss (GLP-1)

    compounded semaglutide and tirzepatide by injection, plus branded GLP-1s through insurance

Pros & cons

Pros

  • Transparent flat cash-pay pricing with shipping included; recent large price cuts (semaglutide $175 to $99, tirzepatide $325 to $199)
  • Mandatory live video consultation with board-certified obesity-medicine physicians and registered-dietitian support (not async questionnaire-only)
  • Strong, high-volume consumer sentiment (Trustpilot ~4.4 / ~15,600 reviews)

Cons

  • Washington DOH Limited Stop Service order against Mochi's own Aequita compounding pharmacy for untrained staff and sterile-compounding deficiencies; reported contamination; pharmacy closed 2025
  • Sued by Eli Lilly and Novo Nordisk for deceptive marketing of compounded GLP-1s
  • Cancellation is difficult and prescription sales are final/nonrefundable; many complaints of continued billing after cancellation (BBB B-, ~1,296 complaints)
  • Compounded medications are not FDA-approved; we could not find published BMI/age eligibility thresholds (its /eligibility page returned 404), so we have not established that they are unpublished

The bottom line

Mochi Health suits people who want a clinically supervised GLP-1 programme with a real video visit and a price published before they sign up. Weigh that against a regulator’s action against its own compounding pharmacy, two pending manufacturer lawsuits, and a documented pattern of cancellation and refund complaints — and expect to manage the subscription closely.

What changed & why

This brand's own history — every re-review and methodology recompute, logged. Rankings change when the evidence or the rules change, never for payment. See the site-wide methodology ledger for version history.

  1. Sep 18, 2026Initial score5.54

    Mochi Health's Operator Trust Score first recorded at 5.54 out of 10 — the earliest score in this log.

Review score changes

The timeline above is this brand's Operator Trust Score. Each review below is scored separately, and keeps its own history.

  • Weight Management / GLP-1 review— last changed Sep 14, 2026See changes

Work at Mochi Health?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Completeness was not recorded for this score · 6 sources cited

Regulatory

Reviews

Other

What we couldn't verify

  • joinmochi.com/pricing and /eligibility returned 404; on-site pricing/eligibility corroborated via aggregators. Trustpilot now verified 4.4/16,273 (rendered fetch 2026-07-24).
  • Specific BMI/age eligibility thresholds are not published on Mochi's site (assessed only during the live consult).
  • Current active compounding-pharmacy partners (Seven Cells, Drug Crafters) and their 503A/503B status post-Aequita are reported by third parties, not confirmed on a primary Mochi page.
  • Whether Mochi specifically received a Sept-2025 FDA marketing warning letter (vs the industry-wide wave) was not confirmed from a primary FDA source.
  • Withdrawn — Some customers reported serious illness after injections. "Some customers reported serious illness after injections" is WITHDRAWN. It is an affirmative ADVERSE claim, and the source is a news digest summarising KING 5's reporting (fetched 2026-08-10) — not a primary record. Adverse claims require a primary source; no FDA adverse-event record, regulator finding or registry entry establishes patient illness attributable to Mochi.
  • Withdrawn — Mochi's LegitScript certification. Mochi's LegitScript certification is WITHDRAWN as a stated fact. The source returned HTTP 403 (recorded as retrieval-failed, not disproved), and the claim appears nowhere on joinmochi.com/weight-loss (fetched 2026-08-10). Mirrors the treatment applied to Sprout Health's unverifiable LegitScript claim. SPLIT 2026-08-25: this entry previously bundled the "all 50 states + DC" availability claim with the LegitScript one and withdrew both. The availability half was REINSTATED on 2026-08-11 — "Correction in Mochi's favour: its availability in all 50 states is stated plainly on its own About page… it is restored" — but this entry was never updated, so gaps[] and the review history contradicted each other on a published page. Only the LegitScript half remains withdrawn. Recorded separately and not decided here: the read that reinstated availability was a raw fetch of joinmochi.com, which is now refused on terms — an open question, not a reason to re-withdraw.
  • Withdrawn — Mochi's HIPAA-compliance and LegitScript claims. Mochi's HIPAA-compliance and LegitScript claims are WITHDRAWN as sourced facts: the third-party page asserting them returned HTTP 403, and joinmochi.com/weight-loss states neither (fetched 2026-08-10). The verified San Francisco address is not in dispute; the compliance claims are simply unverified.
  • data-privacy-security: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. The withdrawn claim was a third party's assertion that Mochi is HIPAA compliant. We found no privacy or HIPAA page on joinmochi.com to check it against (/privacy and /legal both 404). Absent a page to read, we have not established non-disclosure — only that we could not find it.
  • glp1-titration-autonomy: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. The withdrawn claim was "some customers reported serious illness after injections" — an ADVERSE claim WE published and could not source to a primary record. Leaving a subscore penalty on Mochi for an accusation we retracted is the single most objectionable form of this defect.
  • Withdrawn — Claims that Aequita Pharmacy "illegally imported cheap GLP-1 bulk ingredients" and "substituted medical-grade supplies with Alibaba vials". Claims that Aequita Pharmacy "illegally imported cheap GLP-1 bulk ingredients" and "substituted medical-grade supplies with Alibaba vials" are WITHDRAWN. They rested solely on a KING 5 investigation which we could not retrieve (HTTP 403 to a direct fetch, timeout to our fetcher), and the Washington DOH notice — which we CAN retrieve — cites untrained staff, inadequate supervision and sterile-procedure failures, but says nothing about importation or vial substitution. Withdrawn for want of a retrievable source, not disproved. (2026-08-11)
  • Withdrawn — unlicensed temporary workers picked up at home improvement store parking lots. Claims that Aequita used "unlicensed temporary workers picked up at home improvement store parking lots" and that "at least three GLP-1 prescriptions expired nearly nine months before mailing to patients" are WITHDRAWN — KING 5-only, and unretrievable by us (403 / timeout). The Washington DOH notice covers untrained and unsupervised staff but neither of those specifics. Withdrawn for want of a retrievable source, not disproved. (2026-08-11)
  • Withdrawn — at least three GLP-1 prescriptions expired nearly nine months before mailing to patients. Claims that Aequita used "unlicensed temporary workers picked up at home improvement store parking lots" and that "at least three GLP-1 prescriptions expired nearly nine months before mailing to patients" are WITHDRAWN — KING 5-only, and unretrievable by us (403 / timeout). The Washington DOH notice covers untrained and unsupervised staff but neither of those specifics. Withdrawn for want of a retrievable source, not disproved. (2026-08-11)
  • Withdrawn — figure "~20,000 prescriptions per week at peak". The figure "~20,000 prescriptions per week at peak" is WITHDRAWN. NBC Bay Area attributed it to "inspectors said in their findings" — a paraphrase of an upstream regulator record — and the Washington DOH notice we CAN retrieve contains no volume figure of any kind (checked 2026-08-11). We do not keep a number that reaches us by paraphrase. Separately, the "safety scandal" characterisation is withdrawn: NBC sourced patient-harm claims to whistleblower accounts it obtained, and no primary record establishes patient harm. (2026-08-11)
Last reviewed Sep 14, 2026View the ledger